Luke Selth

Professor Luke Selth is Head of Prostate Cancer Research at Flinders Health and Medical Research Institute (FHMRI), Co-Director of FHMRI's Cancer Impact program, and a Cancer Council SA Beat Cancer Principal Research Fellow (2020-2025). He is affiliated with Flinders University (College of Medicine and Public Health) and holds an adjunct position at the University of Adelaide.

• Education: Bachelor of Biotechnology (Flinders University), PhD in Molecular Virology (University of Adelaide), Postdoctoral studies at Cancer Research UK’s London Research Institute (EMBO Fellowship)

Selth leads an internationally recognized research program focused on androgen receptor signaling, cancer cell plasticity, and novel therapies for prostate cancer. His work integrates epigenetic mechanisms, molecular techniques, and omics approaches to address therapy resistance and improve treatment outcomes.

Recent publications span high-impact journals like Nature Medicine and Science Translational Medicine, emphasizing transcriptomics, metabolic regulation, and therapeutic targeting in prostate cancer. His research trends include cyclin-dependent kinases in transcriptional deregulation, surgical margin analysis, and ferroptosis constraints in cancer progression.

Scientific Awards

• Young Investigator Awards (Prostate Cancer Foundation of Australia and USA Prostate Cancer Foundation)
• AMGEN Prize for Excellence in Biotechnology Research (2000)
• South Australian Young Tall Poppy Science Award (2013)
• Rob Sutherland Award (2019)

Selth serves on the Scientific Advisory Committee for the South Australian Genomics Centre and the Freemasons Centre for Male Health and Wellbeing. He holds editorial roles at Endocrine-Related Cancer and Cancer Research Communications, with funding from NHMRC, Cancer Australia, Movember, and other major organizations.